{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:39:16Z","timestamp":1773275956198,"version":"3.50.1"},"reference-count":60,"publisher":"FapUNIFESP (SciELO)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arq Bras Endocrinol Metab"],"published-print":{"date-parts":[[2009,3]]},"abstract":"<jats:p>Ancillary therapies for weight management, consisting mainly of diet and exercise programs that incorporate variable levels of lifestyle modification techniques, are frequently ineffective to achieve clinically meaningful weight loss and maintenance. Although pharmacological treatment of obesity is widely used in most countries, the number of available drugs is still very limited. The most widely used anti-obesity agents are sibutramine and orlistat, both available in clinical practice for about a decade. A large number of clinical trials have demonstrated that both agents are safe and well tolerated, with a level of efficacy in the moderate weight loss recommended by the most relevant clinical guidelines. Several studies have assessed the efficacy and safety of sibutramine and orlistat in adolescents and also for the treatment of some associated conditions in adults, including type 2 diabetes, polycystic ovary syndrome and binge eating disorder. The positive results of these studies suggest an expanding role for both agents, not only for the treatment of obesity, but also for associated conditions. After the efficacy of orlistat for the prevention of type 2 diabetes demonstrated in the XENDOS study, the results of SCOUT study are awaited for a better evaluation of sibutramine impact on cardiovascular outcomes.<\/jats:p>","DOI":"10.1590\/s0004-27302009000200018","type":"journal-article","created":{"date-parts":[[2009,5,21]],"date-time":"2009-05-21T03:43:56Z","timestamp":1242877436000},"page":"262-270","source":"Crossref","is-referenced-by-count":16,"title":["The first decade of sibutramine and orlistat: a reappraisal of their expanding roles in the treatment of obesity and associated conditions"],"prefix":"10.1590","volume":"53","author":[{"given":"Walmir","family":"Coutinho","sequence":"first","affiliation":[{"name":"Sociedade Brasileira de Endocrinologia e Metabologia, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"530","reference":[{"key":"ref1","series-title":"Obesity: preventing and managing the global epidemic. Report of a WHO consultation","year":"2000"},{"issue":"11","key":"ref2","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1001\/jama.287.11.1382-JMN0320-2-1","article-title":"Epidemic of obesity expands its spread to developing countries","volume":"287","author":"Friedrich MJ","year":"2002","journal-title":"JAMA."},{"issue":"7","key":"ref3","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1590\/S0102-311X2007000700025","article-title":"The burden of hospitalization due to overweight and obesity in Brazil","volume":"23","author":"Sichieri R","year":"2007","journal-title":"Cad Saude Publica."},{"issue":"9403","key":"ref4","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0140-6736(03)15268-3","article-title":"Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies","volume":"363","author":"WHO Expert Consultation","year":"2004","journal-title":"Lancet."},{"issue":"9","key":"ref5","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.2105\/AJPH.82.9.1251","article-title":"Weight loss attempts in adults: goals, duration, and rate of weight loss","volume":"82","author":"Williamson DF","year":"1992","journal-title":"Am J Public Health."},{"issue":"2","key":"ref6","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1207\/s15324796abm2702_4","article-title":"The weight loss experience: a descriptive analysis","volume":"27","author":"Jeffery RW","year":"2004","journal-title":"Ann Behav Med."},{"issue":"7","key":"ref7","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1001\/archinte.160.7.898","article-title":"Overweight, obesity, and health risk","volume":"160","author":"National Task Force on the Prevention and Treatment of Obesity","year":"2000","journal-title":"Arch Intern Med."},{"issue":"21","key":"ref8","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1161\/01.CIR.97.21.2099","article-title":"American Heart Association call to action: obesity as a major risk factor for coronary heart disease","volume":"97","author":"Eckel RH","year":"1998","journal-title":"AHA Nutrition Committee. Circulation"},{"issue":"6","key":"ref9","first-page":"397","article-title":"Beneficial health effects of modest weight loss","volume":"16","author":"Goldstein DJ","year":"1992","journal-title":"Int J Obes Relat Metab Disord."},{"issue":"2","key":"ref10","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1001\/archinte.161.2.218","article-title":"Benefits of lifestyle modification in the pharmacologic treatment of obesity: a randomized trial","volume":"161","author":"Wadden TA","year":"2001","journal-title":"Arch Intern Med."},{"issue":"20","key":"ref11","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1056\/NEJMoa050156","article-title":"Randomized Trial of Lifestyle Modification and Pharmacotherapy for Obesity","volume":"353","author":"Thomas A","year":"2005","journal-title":"N Engl J Med."},{"key":"ref12","first-page":"51S","article-title":"Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: The Evidence Report","volume":"6","year":"1998","journal-title":"National Institute of Health Obes Res."},{"issue":"1","key":"ref13","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1590\/S0004-27302000000100014","article-title":"A farmacoterapia da obesidade nos consensos","volume":"44","author":"Coutinho WF","year":"2000","journal-title":"Arq Bras Endocrinol Metab."},{"issue":"1","key":"ref14","doi-asserted-by":"crossref","first-page":"22","DOI":"10.47102\/annals-acadmedsg.V38N1p22","article-title":"Medical Management of Obesity and its Complications","volume":"38","author":"Caterson ID","year":"2009","journal-title":"Ann Acad Med Singapore."},{"issue":"5","key":"ref15","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/oby.2003.85","article-title":"Effects of sibutramine on binge eating, hunger, and fullness in a laboratory human feeding paradigm","volume":"11","author":"Mitchell JE","year":"2003","journal-title":"Obes Res."},{"issue":"2","key":"ref16","first-page":"286","article-title":"[Evaluation of the sibutramine effect on satiety with a visual analogue scale in obese adolescents]","volume":"49","author":"Corr\u00eaa LL","year":"2005","journal-title":"Arq Bras Endocrinol Metabol."},{"issue":"10","key":"ref17","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1038\/sj.ijo.0801059","article-title":"The effect of sibutramine on energy expenditure and appetite during chronic treatment without dietary restriction","volume":"23","author":"Hansen DL","year":"1999","journal-title":"Int J Obes Relat Metab Disord."},{"issue":"1","key":"ref18","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0014-2999(02)02226-4","article-title":"Comparison of the thermogenic and hypophagic effects of sibutramine's metabolite 2 and other monoamine reuptake inhibitors","volume":"452","author":"Liu YL","year":"2002","journal-title":"Eur J Pharmacol."},{"key":"ref19","first-page":"S100","article-title":"Weight reduction by sibutramine in obese subjects in primary care medicine: the S. A.T. study","volume":"24","author":"Hauner H","year":"2000","journal-title":"Int J Obes Relat Metab Disord."},{"issue":"1","key":"ref20","doi-asserted-by":"crossref","first-page":"125","DOI":"10.2337\/diacare.26.1.125","article-title":"A randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin","volume":"26","author":"McNulty SJ","year":"2003","journal-title":"Diabetes Care."},{"issue":"7","key":"ref21","doi-asserted-by":"crossref","first-page":"532","DOI":"10.7326\/0003-4819-142-7-200504050-00012","article-title":"Meta-analysis: pharmacologic treatment of obesity","volume":"142","author":"Li Z","year":"2005","journal-title":"Ann Intern Med."},{"issue":"9248","key":"ref22","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1016\/S0140-6736(00)03491-7","article-title":"Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance","volume":"356","author":"James WP","year":"2000","journal-title":"Lancet."},{"issue":"3","key":"ref23","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1210\/jc.2004-0263","article-title":"Treatment of obese adolescents with sibutramine: a randomized, double-blind, controlled study","volume":"90","author":"Godoy-Matos A","year":"2005","journal-title":"J Clin Endocrinol Metab."},{"issue":"14","key":"ref24","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1001\/jama.289.14.1805","article-title":"Behavior therapy and sibutramine for the treatment of adolescent obesity: A randomized controlled trial","volume":"289","author":"Berkowitz RL","year":"2003","journal-title":"JAMA."},{"issue":"2","key":"ref25","doi-asserted-by":"crossref","first-page":"81","DOI":"10.7326\/0003-4819-145-2-200607180-00005","article-title":"Effects of sibutramine treatment in obese adolescents: A randomized trial","volume":"145","author":"Berkowitz RI","year":"2006","journal-title":"Ann Intern Med."},{"issue":"11","key":"ref26","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1001\/archpsyc.60.11.1109","article-title":"A randomized, double blind, placebo-controlled study of sibutramine in the treatment of binge-eating disorder","volume":"60","author":"Appolinario JC","year":"2003","journal-title":"Arch Gen Psychiatry."},{"issue":"1","key":"ref27","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/BF02850181","article-title":"Use of sibutramine, an inhibitor of the reuptake of serotonin and noradrenaline, in the treatment of binge eating disorder: a placebo-controlled study","volume":"22","author":"Milano W","year":"2005","journal-title":"Adv Ther."},{"issue":"14","key":"ref28","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1001\/archinte.160.14.2185","article-title":"Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial","volume":"160","author":"McMahon FG","year":"2000","journal-title":"Arch Intern Med."},{"key":"ref29","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/sj.ijo.0802887","article-title":"Influence of sibutramine on blood pressure: evidence from placebo-controlled trials","volume":"29","author":"Jordan J","year":"2005","journal-title":"Int J Obes."},{"issue":"3","key":"ref30","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/j.1463-1326.2008.00930.x","article-title":"Blood pressure changes associated with sibutramine and weight management: an analysis of the 6-week leading period of the Sibutramine Cardiovascular Outcomes (SCOUT) Trial","volume":"11","author":"Sharma AM","year":"2009","journal-title":"Diabetes Obes Metab."},{"issue":"19","key":"ref31","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1161\/01.CIR.0000036370.31856.73","article-title":"Paradoxical effect of sibutramine on autonomic cardiovascular regulation","volume":"106","author":"Birkenfeld A","year":"2002","journal-title":"Circulation."},{"issue":"23","key":"ref32","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1093\/eurheartj\/ehm217","article-title":"Cardiovascular responses to weight management and sibutramine in high-risk subjects: an analysis from the SCOUT trial","volume":"28","author":"Torp-Pedersen C","year":"2007","journal-title":"Eur Heart J."},{"issue":"5","key":"ref33","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/FJC.0b013e31818713d6","article-title":"Tolerability of sibutramine during a 6-week treatment period in high-risk patients with cardiovascular disease and\/or diabetes: a preliminary analysis of the Sibutramine Cardiovascular Outcomes (SCOUT) Trial","volume":"52","author":"Maggioni AP","year":"2008","journal-title":"J Cardiovasc Pharmacol."},{"key":"ref34","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1038\/sj.ijo.0803733","article-title":"The obese older female patient: CV risk and the SCOUT study","volume":"31","author":"Coutinho WF","year":"2007","journal-title":"Int J Obes."},{"issue":"1","key":"ref35","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1467-789X.2004.00125.x","article-title":"A systematic review of the clinical effectiveness of orlistat used for the management of obesity","volume":"5","author":"O'Meara S","year":"2004","journal-title":"Obes Rev."},{"issue":"6","key":"ref36","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1093\/ajcn\/80.6.1461","article-title":"Changes in body weight and serum lipid profile in obese patients treated with orlistat in addition to a hypocaloric diet: a systematic review of randomized clinical trials","volume":"80","author":"Hutton B","year":"2004","journal-title":"Am J Clin Nutr."},{"issue":"10","key":"ref37","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/oby.2001.79","article-title":"Orlistat inhibits dietary cholesterol absorption","volume":"9","author":"Mittendorfer B","year":"2001","journal-title":"Obes Res."},{"issue":"1","key":"ref38","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1093\/ajcn\/79.1.22","article-title":"Effects of equal weight loss with orlistat and placebo on body fat and serum fatty acid composition and insulin resistance in obese women","volume":"79","author":"Tiikkainen M","year":"2004","journal-title":"Am J Clin Nutr."},{"issue":"1","key":"ref39","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2337\/diacare.27.1.155","article-title":"XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients","volume":"27","author":"Torgerson JS","year":"2004","journal-title":"Diabetes Care."},{"issue":"1","key":"ref40","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.atherosclerosis.2004.11.023","article-title":"Effect of orlistat on postprandial lipemia, NMR lipoprotein subclass profiles and particle size","volume":"180","author":"Sutera PM","year":"2005","journal-title":"Atherosclerosis."},{"issue":"5","key":"ref41","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.cgh.2006.02.004","article-title":"A double-blind randomized placebocontrolled trial of orlistat for the treatment of nonalcoholic fatty liver disease","volume":"4","author":"Zelber-Sagi S","year":"2006","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"1","key":"ref42","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.diabres.2004.05.012","article-title":"Orlistat for obesity: benefits beyond weight loss","volume":"67","author":"Hsieh CJ","year":"2005","journal-title":"Diabetes Res Clin Pract."},{"issue":"4","key":"ref43","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1463-1326.2008.00970.x","article-title":"Orlistat 120 mg improves glycaemic control in type 2 diabetic patients with or without concurrent weight loss","volume":"11","author":"Jacob S","year":"2009","journal-title":"Diabetes Obes Metab."},{"issue":"1","key":"ref44","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2337\/diacare.27.1.33","article-title":"Orlistat on insulin resistance, regional adiposity, and fatty acids in type 2 diabetes mellitus","volume":"27","author":"Kelley DE","year":"2004","journal-title":"Diabetes Care."},{"issue":"5","key":"ref45","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.2337\/diacare.27.5.1077","article-title":"Orlistat augments postprandial increases in glucagon-like peptide 1 in obese type 2 diabetic patients","volume":"27","author":"Damci T","year":"2004","journal-title":"Diabetes Care."},{"issue":"7","key":"ref46","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/oby.2002.87","article-title":"Three month tolerability of orlistat in adolescents with obesity related comorbid conditions","volume":"10","author":"McDuffie JR","year":"2002","journal-title":"Obes Res."},{"issue":"23","key":"ref47","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1001\/jama.293.23.2873","article-title":"Effect of orlistat on weight and body composition in obese adolescents.: a randomized controlled trial","volume":"293","author":"Chanoine JP","year":"2005","journal-title":"JAMA."},{"issue":"10","key":"ref48","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1038\/oby.2005.208","article-title":"Effect of orlistat in obese patients with binge eating disorder","volume":"13","author":"Golay A","year":"2005","journal-title":"Obes Res."},{"issue":"10","key":"ref49","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.biopsych.2005.03.001","article-title":"Cognitive behavioral therapy guided self-help and orlistat for the treatment of binge eating disorder: a randomized, double-blind, placebo-controlled trial","volume":"57","author":"Grilo CM","year":"2005","journal-title":"Biol Psychiatry."},{"issue":"4","key":"ref50","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.metabol.2005.10.011","article-title":"Short-term effect of orlistat on dietary glycotoxins in healthy women and women with polycystic ovary syndrome","volume":"55","author":"Diamanti-Kandarakis E","year":"2006","journal-title":"Metabolism."},{"issue":"4","key":"ref51","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.fertnstert.2007.04.043","article-title":"Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels","volume":"89","author":"Panidis D","year":"2008","journal-title":"Fertil Steril."},{"issue":"6","key":"ref52","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/oby.2000.53","article-title":"Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: a placebo-controlled trial","volume":"8","author":"Wadden TA","year":"2000","journal-title":"Obes Res."},{"issue":"2","key":"ref53","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1081\/ERC-200027356","article-title":"Comparison of efficacy of sibutramine or orlistat versus their combination in obese women","volume":"30","author":"Sari R","year":"2004","journal-title":"Endocr Res."},{"issue":"10","key":"ref54","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.biopha.2004.09.006","article-title":"Efficacy of sibutramine, orlistat and combination therapy on short-term weight management in obese patients","volume":"58","author":"Kaya A","year":"2004","journal-title":"Biomed Pharmacother."},{"issue":"3","key":"ref55","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1620\/tjem.202.173","article-title":"Orlistat, sibutramine, or combination therapy: which performs better on waist circumference in relation with body mass index in obese patients?","volume":"202","author":"Aydin N","year":"2004","journal-title":"Tohoku J Exp Med","ISSN":"https:\/\/id.crossref.org\/issn\/0040-8727","issn-type":"print"},{"issue":"21","key":"ref56","doi-asserted-by":"crossref","first-page":"iii","DOI":"10.3310\/hta8210","article-title":"Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement","volume":"8","author":"Avenell A","year":"2004","journal-title":"Health Technol Assess."},{"issue":"12","key":"ref57","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1038\/ijo.2008.189","article-title":"Cost-effectiveness of pharmacological anti-obesity treatments: a systematic review","volume":"32","author":"Neovius M","year":"2008","journal-title":"Int J Obes."},{"issue":"1","key":"ref58","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1037\/0022-006X.65.1.79","article-title":"What is a reasonable weight loss? Patients' expectations and evaluations of obesity treatment outcomes","volume":"65","author":"Foster GD","year":"1997","journal-title":"J Consult Clin Psychol."},{"issue":"7631","key":"ref59","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1136\/bmj.39385.413113.25","article-title":"Long term pharmacotherapy for obesity and overweight: updated meta-analysis","volume":"335","author":"Rucker D","year":"2007","journal-title":"BMJ."},{"issue":"3","key":"ref60","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1185\/030079905X38132","article-title":"A review of the metabolic effects of sibutramine","volume":"21","author":"Filippatos TD","year":"2005","journal-title":"Curr Med Res Opin."}],"container-title":["Arquivos Brasileiros de Endocrinologia &amp; Metabologia"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/abem\/v53n2\/a18v53n2.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T18:25:12Z","timestamp":1710354312000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0004-27302009000200018&lng=en&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3]]},"references-count":60,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,3]]}},"alternative-id":["S0004-27302009000200018"],"URL":"https:\/\/doi.org\/10.1590\/s0004-27302009000200018","relation":{},"ISSN":["0004-2730"],"issn-type":[{"value":"0004-2730","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,3]]}}}